Seeing further.


We’re advancing our RNA-based treatments so patients with cancers and rare diseases can enjoy the moments that matter.

Learn More

Transforming Immunity. Restoring Hope.

We’re committed to redefining the treatment of certain cancers and rare diseases.

Learn More

Scientists. Believers. People.

At Idera, we’re working hard to translate our nucleic acid science into life-changing medicines.

Discover Idera

The Latest

Keep up with what’s happening at Idera Pharmaceuticals.


Idera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update

IMO-2125 Advances to Phase 2 Clinical Trial in PD-1 Refractory Melanoma CAMBRIDGE, Mass. and… Read more 

Idera Pharmaceuticals Announces Organizational Update

Antisense Pioneer and Idera Founder Dr. Sudhir Agrawal Set to Retire CAMBRIDGE, Mass. and EXTON,… Read more 

Idera Pharmaceuticals Advances Investigational Treatment – Intratumoral IMO-2125 in Combination with Ipilimumab - for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma

All objectives successfully met in Phase 1 portion of combination trial and the company is now… Read more 

Learn More


Tue, 23 May 2017 23:23:22 GMT

Idera Pharmaceuticals, Inc. Calendar Events

A Collection of Idera Pharmaceuticals, Inc. Calendar Events… Read more 

Learn More